Vanda Receives Negative Opinion for Marketing Authorization from the European Medicines Agency on Fanaptumtm for the Treatment of Schizophrenia
WASHINGTON, Nov. 10, 2017 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) announced today the refusal of the marketing authorization application (MAA) of Fanaptumtm (oral iloperidone tablets) for the treatment of schizophrenia in adult patients in the European Union. In July 2017, the Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion, recommending the refusal of the Fanaptumtm MAA. Vanda requested a re-examination of the initial opinion. After considering the grounds for this request, the CHMP re-examined the opinion and confirmed the refusal of the Fanaptumtm MAA on November 9, 2017.
About Vanda Pharmaceuticals Inc. Vanda is a global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com.
About Fanapt®
For full U.S. Prescribing Information for Fanapt®, including indication, Boxed Warnings and Important Safety Information, visit our Web site at www.fanapt.com.
Investor Contact: Jim Kelly Executive Vice President & Chief Financial Officer Vanda Pharmaceuticals Inc. (202) 734-3428 [email protected]
REI Path Ahead Ventures is celebrating 16 emerging companies completing its Embark program, bringing the latest products and experiences to the outdoor industry. Embark is a three-month curriculum created in partnership with Founded Outdoors to...
BrainSell, the growth enablement company specializing in helping clients grow with top-of-the-line business technology solutions, has promoted Kevin Cook to Chief Technology Officer (CTO). Cook's 15 years at BrainSell, working across business...
Ferrilli, a leading provider of technology solutions for higher education institutions, proudly announces its recognition as the Ellucian Implementation Partner of the Year for 2023. This esteemed award marks the second consecutive year that Ferrilli...
A modified, upgraded, and perfectly preserved 2006 Pontiac GTO sponsored by CRC Industries will be auctioned May 15, 2024 with all proceeds going to TechForce Foundation, a nonprofit organization that funds education for and champions young people...
CareHive Health, a pioneer in data-driven, digital-first, white glove navigation solutions, proudly announces the appointment of Julianne Bride, MBA, as CareHive's Vice President of Strategic Partnerships and Client Success.
Julianne Bride's...
Abzena, the leading end-to-end integrated CDMO for complex biologics and bioconjugates, has announced the launch of its enhanced bioassay platform EpiScreen® 2.0, a comprehensive suite of assays that predict and evaluate potential risks of...
